1. Home
  2. VRTX vs MDT Comparison

VRTX vs MDT Comparison

Compare VRTX & MDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • MDT
  • Stock Information
  • Founded
  • VRTX 1989
  • MDT 1949
  • Country
  • VRTX United States
  • MDT Ireland
  • Employees
  • VRTX N/A
  • MDT N/A
  • Industry
  • VRTX EDP Services
  • MDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • VRTX Technology
  • MDT Health Care
  • Exchange
  • VRTX Nasdaq
  • MDT Nasdaq
  • Market Cap
  • VRTX 96.6B
  • MDT 114.9B
  • IPO Year
  • VRTX 1991
  • MDT N/A
  • Fundamental
  • Price
  • VRTX $434.67
  • MDT $96.19
  • Analyst Decision
  • VRTX Buy
  • MDT Buy
  • Analyst Count
  • VRTX 26
  • MDT 17
  • Target Price
  • VRTX $489.17
  • MDT $103.80
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • MDT 6.0M
  • Earning Date
  • VRTX 11-03-2025
  • MDT 11-18-2025
  • Dividend Yield
  • VRTX N/A
  • MDT 2.95%
  • EPS Growth
  • VRTX N/A
  • MDT 21.95
  • EPS
  • VRTX 14.22
  • MDT 3.62
  • Revenue
  • VRTX $11,723,300,000.00
  • MDT $34,200,000,000.00
  • Revenue This Year
  • VRTX $10.95
  • MDT $7.97
  • Revenue Next Year
  • VRTX $9.55
  • MDT $5.47
  • P/E Ratio
  • VRTX $30.55
  • MDT $26.55
  • Revenue Growth
  • VRTX 10.33
  • MDT 4.98
  • 52 Week Low
  • VRTX $362.50
  • MDT $79.29
  • 52 Week High
  • VRTX $519.68
  • MDT $99.37
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 63.79
  • MDT 62.50
  • Support Level
  • VRTX $406.67
  • MDT $89.36
  • Resistance Level
  • VRTX $430.71
  • MDT $94.60
  • Average True Range (ATR)
  • VRTX 11.47
  • MDT 1.47
  • MACD
  • VRTX 0.70
  • MDT 0.53
  • Stochastic Oscillator
  • VRTX 82.90
  • MDT 93.74

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About MDT Medtronic plc.

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Share on Social Networks: